Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Rowena Callis"'
Autor:
Donald Ogilvie, Robert W. Wilkinson, Bernard Barlaam, Paul Smith, Konstantina Grosios, Elizabeth Mills, Rowena Callis, Sara Davenport, Gayle Marshall, Sarah Beck, Judith Anderton, Cath Trigwell, John Vincent, Georgina Speake, Teresa Klinowska, D. Mark Hickinson
Supplementary Data from AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a7713f65d79a8772a0aabd9ebd0f375
https://doi.org/10.1158/1078-0432.22442994
https://doi.org/10.1158/1078-0432.22442994
Autor:
Donald Ogilvie, Robert W. Wilkinson, Bernard Barlaam, Paul Smith, Konstantina Grosios, Elizabeth Mills, Rowena Callis, Sara Davenport, Gayle Marshall, Sarah Beck, Judith Anderton, Cath Trigwell, John Vincent, Georgina Speake, Teresa Klinowska, D. Mark Hickinson
Purpose: To test the hypothesis that simultaneous, equipotent inhibition of epidermal growth factor receptor (EGFR; erbB1), erbB2 (human epidermal growth factor receptor 2), and erbB3 receptor signaling, using the novel small-molecule inhibitor AZD89
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc3df99d9418da872c459a0c2702594c
https://doi.org/10.1158/1078-0432.c.6519609.v1
https://doi.org/10.1158/1078-0432.c.6519609.v1
Autor:
Dmitri I. Svergun, Huawei Chen, Romel Bobby, Natalie Stratton, Danette L. Daniels, Scott Boiko, Rowena Callis, Yi Yao, Graeme R. Robb, Alfred A. Rabow, Mark S. B. McAlister, Graeme Walker, Joe Patel, Matthew B. Robers, Derek Ogg, Sakina Saif, Liz Flavell, Philip Petteruti, Austin Dulak, Ian L. Dale, Jacqui Méndez, Thomas A. Jowitt, Michael J. Waring, David Matthew Wilson, David Whittaker, Wenxian Wang, Edwin Clark, Alexey Kikhney, Geoff Holdgate, Rob H. Bradbury
Publikováno v:
Nature Chemical Biology. 12:1097-1104
Proteins of the bromodomain and extraterminal (BET) family, in particular bromodomain-containing protein 4 (BRD4), are of great interest as biological targets. BET proteins contain two separate bromodomains, and existing inhibitors bind to them monov
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2383592d971df225a15fa5861356ca2a
https://doi.org/10.1038/nchembio.2210
https://doi.org/10.1038/nchembio.2210
Autor:
Joe Patel, Mark A. Graham, Maureen Hattersley, Stephen Stokes, David Whittaker, Carr Gregory Richard, David Whalley, Edwin Clark, Craig A. Roberts, Gail L. Wrigley, Alfred A. Rabow, Graeme Walker, Christopher R. Jones, Natalie Stratton, Michael J. Waring, Rowena Callis, Lyman Feron, Robert Hugh Bradbury, Steve C. Glossop, Huawei Chen, Lara Ward, Anil Patel, Gilles Ouvry, Scott G. Lamont
Publikováno v:
Journal of Medicinal Chemistry. 59:7801-7817
Here we report the discovery and optimization of a series of bivalent bromodomain and extraterminal inhibitors. Starting with the observation of BRD4 activity of compounds from a previous program, the compounds were optimized for BRD4 potency and phy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5c6c7a1841e4b9e6991aa022e6aedcc0
https://doi.org/10.1021/acs.jmedchem.6b00070
https://doi.org/10.1021/acs.jmedchem.6b00070
Autor:
Graeme Walker, Tim Ikeda, Amalia Paunovic, Rowena Callis, Carly Simpson, Karen Roberts, Nick Turton, Eric Tang
Publikováno v:
SLAS Technology. 21:76-89
Since the adoption of Labcyte Echo Acoustic Droplet Ejection (ADE) technology by AstraZeneca in 2005, ADE has become the preferred method for compound dosing into both biochemical and cell-based assays across AstraZeneca research and development glob
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae5a3c04fa963b20d04246d2200a6e9d
https://doi.org/10.1177/2211068215595212
https://doi.org/10.1177/2211068215595212
Autor:
Anne Marie Mazzola, Graham Richmond, Craig S. Donald, Rachel Rowlinson, Celina M. D'Cruz, Michael Hulse, Camila de Almeida, Gareth M. Davies, Zena Wilson, David M. Andrews, Peter Ballard, Gordon S. Currie, Hazel M. Weir, Rowena Callis, Robert Hugh Bradbury, Jon Curwen, Mandy Lawson, Richard A. Norman, David Buttar, Ermira Pazolli, Chris De Savi, Brendon Ladd, Steve Powell, Alfred A. Rabow, Graeme Walker, Michael Tonge
Publikováno v:
Cancer Research. 75:DDT01-03
With over 70% of breast cancers expressing estrogen receptor alpha protein (ERα), treatment with either anti-hormonal therapies that directly block ERα function (e.g. tamoxifen) or therapies that block the production of estrogen itself (e.g. anastr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::847cf1a8960a2a6867f31abb4a95bdee
https://doi.org/10.1158/1538-7445.am2015-ddt01-03
https://doi.org/10.1158/1538-7445.am2015-ddt01-03
Autor:
Craig S. Donald, Galith Karoutchi, Syeed Hussain, Peter Ballard, Gordon S. Currie, Barry R. Hayter, Hazel M. Weir, H. Gingell, Richard A. Norman, Steven C. Glossop, David Buttar, Lyman Feron, Zena Wilson, Stuart E. Pearson, Camila de Almeida, Christopher D. Davies, Rowena Callis, Philip A. MacFaul, Thomas A. Moss, Chris De Savi, Alfred A. Rabow, David M. Andrews, Graeme Walker, Michael Tonge, Scott G. Lamont, Jon Curwen, Robert Hugh Bradbury
Publikováno v:
Journal of Medicinal Chemistry. 58:8128-8140
The discovery of an orally bioavailable selective estrogen receptor downregulator (SERD) with equivalent potency and preclinical pharmacology to the intramuscular SERD fulvestrant is described. A directed screen identified the 1-aryl-2,3,4,9-tetrahyd
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a9d21c50ca9de0e32e23964631039a67
https://doi.org/10.1021/acs.jmedchem.5b00984
https://doi.org/10.1021/acs.jmedchem.5b00984
Autor:
Rowena Callis, Alfred A. Rabow, Graeme Walker, Michael Tonge, Karen Jones, Mairi Challinor, Robert Hugh Bradbury, Karen Roberts
Publikováno v:
SLAS Discovery. 20:748-759
Here, we describe an approach to identify novel selective estrogen receptor downregulator (SERD) compounds with improved properties such as oral bioavailability and the potential of increased efficacy compared to currently marketed drug treatments. P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54c700a55c6290ca33b0781db6af2198
https://doi.org/10.1177/1087057115580298
https://doi.org/10.1177/1087057115580298
Autor:
Sébastien L. Degorce, Patrick Ple, Mickaël Maudet, Jennifer H. Pink, Rowena Callis, Andrew Bailey, Bryan Roberts, Chris De Savi, Richard A. Norman, Rémy Morgentin, Aurélien Péru, Richard Ducray, Scott W. Martin, James S. Scott, Gillian M. Lamont, Philip A. MacFaul
Publikováno v:
Journal of Medicinal Chemistry. 58:3522-3533
A novel estrogen receptor down-regulator, 7-hydroxycoumarin (5, SS5020), has been reported with antitumor effects against chemically induced mammary tumors. Here, we report on our own investigation of 7-hydroxycoumarins as potential selective estroge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9cf5b93b8829793733bb4777a0f071a4
https://doi.org/10.1021/acs.jmedchem.5b00066
https://doi.org/10.1021/acs.jmedchem.5b00066
Autor:
Zena Wilson, Jon Curwen, Ermira Pazolli, Michael Hulse, N Reavey, Graeme Walker, Rachel Schiff, A.A. Rabow, Mandy Lawson, Rob H. Bradbury, Steve Powell, Agostina Nardone, Rachel Rowlinson, Celina M. D'Cruz, C. De Savi, Rowena Callis, Hazel M. Weir
Publikováno v:
Cancer Research. 73:P5-09
With over 70% of breast cancers expressing the estrogen receptor alpha (ERa), treatment with either anti-hormonal therapies that directly block ER function (e.g.Tamoxifen) or therapies that block the production of estrogen itself (e.g. aromatase inhi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c923447479bae56bc973afe1a903e8b2
https://doi.org/10.1158/0008-5472.sabcs13-p5-09-20
https://doi.org/10.1158/0008-5472.sabcs13-p5-09-20